• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

突尼斯心房颤动的流行病学特征、管理和结局:来自全国心房颤动登记研究(NATURE-AF)的结果。

Epidemiological characteristics, management, and outcomes of atrial fibrillation in TUNISIA: Results from the National Tunisian Registry of Atrial Fibrillation (NATURE-AF).

机构信息

Hôpital La Rabta, Tunis, Tunisia.

Abderrahman Mami Pneumology and Phthisiology Hospital, Ariana, Tunisia.

出版信息

Clin Cardiol. 2021 Apr;44(4):501-510. doi: 10.1002/clc.23558. Epub 2021 Mar 11.

DOI:10.1002/clc.23558
PMID:33704830
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8027580/
Abstract

BACKGROUND

Contemporary registries on atrial fibrillation (AF) are scare in North African countries.

HYPOTHESIS

In the context of the epidemiological transition, prevalence of valvular AF in Tunisia has decreased and the quality of management is still suboptimal.

METHODS

NATURE-AF is a prospective Tunisian registry, involving consecutive patients with AF from March 1, 2017 to May 31, 2017, with a one-year follow-up period. All the patients with an Electrocardiogram-documented AF, confirmed in the year prior to enrolment were eligible. The epidemiological characteristics and outcomes were described.

RESULTS

A total of 915 patients were included in this study, with a mean age of 64.3 ± 22 years and a male/female sex ratio of 0.93. Valvular AF was identified in 22.4% of the patients. The mean CHA DS VASC score in nonvalvular AF was 2.4 ± 1.6. Monotherapy with antiplatelet agents was prescribed for 13.8% of the patients. However, 21.7% of the subjects did not receive any antithrombotic agent. Oral anticoagulants were prescribed for half of the patients with a low embolic risk score. In 341 patients, the mean time in therapeutic range was 48.87 ± 28.69%. Amiodarone was the most common antiarrhythmic agent used (52.6%). During a 12-month follow-up period, 15 patients (1.64%) had thromboembolism, 53 patients (5.8%) had major hemorrhage, and 52 patients (5.7%) died.

CONCLUSIONS

NATURE-AF has provided systematic collection of contemporary data regarding the epidemiological and clinical characteristics as well as the management of AF by cardiologists in Tunisia. Valvular AF is still prevalent and the quality of anticoagulation was suboptimal.

摘要

背景

北非国家关于心房颤动(AF)的当代注册研究很少。

假设

在流行病学转变的背景下,突尼斯的瓣膜性房颤患病率下降,管理质量仍不理想。

方法

NATURE-AF 是一项前瞻性的突尼斯注册研究,涉及 2017 年 3 月 1 日至 2017 年 5 月 31 日期间连续的 AF 患者,随访期为 1 年。所有经心电图记录的、在登记前 1 年内确诊的 AF 患者均符合条件。描述了流行病学特征和结局。

结果

本研究共纳入 915 例患者,平均年龄为 64.3±22 岁,男女比例为 0.93。瓣膜性 AF 占患者的 22.4%。非瓣膜性 AF 患者的平均 CHA2DS2-VASc 评分为 2.4±1.6。抗血小板药物单药治疗用于 13.8%的患者。然而,21.7%的患者未接受任何抗血栓药物治疗。低栓塞风险评分的患者中,一半给予口服抗凝药物。在 341 例患者中,治疗范围内的平均时间为 48.87±28.69%。胺碘酮是最常用的抗心律失常药物(52.6%)。在 12 个月的随访期间,15 例患者(1.64%)发生血栓栓塞,53 例患者(5.8%)发生大出血,52 例患者(5.7%)死亡。

结论

NATURE-AF 提供了关于突尼斯心脏病专家对 AF 的流行病学和临床特征以及管理的系统当代数据收集。瓣膜性房颤仍然很常见,抗凝质量不理想。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d47/8027580/ebc6b6ddc999/CLC-44-501-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d47/8027580/fdde788a3274/CLC-44-501-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d47/8027580/ebc6b6ddc999/CLC-44-501-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d47/8027580/fdde788a3274/CLC-44-501-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d47/8027580/ebc6b6ddc999/CLC-44-501-g002.jpg

相似文献

1
Epidemiological characteristics, management, and outcomes of atrial fibrillation in TUNISIA: Results from the National Tunisian Registry of Atrial Fibrillation (NATURE-AF).突尼斯心房颤动的流行病学特征、管理和结局:来自全国心房颤动登记研究(NATURE-AF)的结果。
Clin Cardiol. 2021 Apr;44(4):501-510. doi: 10.1002/clc.23558. Epub 2021 Mar 11.
2
A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry.一项在欧洲心脏病学会成员国中进行的关于心房颤动管理的前瞻性调查:EURObservational Research Programme Atrial Fibrillation(EORP-AF)试点综合登记处的基线结果。
Europace. 2014 Mar;16(3):308-19. doi: 10.1093/europace/eut373. Epub 2013 Dec 17.
3
Stroke-prevention strategies in North American patients with atrial fibrillation: The GLORIA-AF registry program.北美心房颤动患者的卒中预防策略:GLORIA-AF注册研究项目
Clin Cardiol. 2018 Jun;41(6):744-751. doi: 10.1002/clc.22936. Epub 2018 May 10.
4
Do physicians correctly calculate thromboembolic risk scores? A comparison of concordance between manual and computer-based calculation of CHADS2 and CHA2 DS2 -VASc scores.医生是否正确计算血栓栓塞风险评分?CHADS2和CHA2 DS2 -VASc评分手动计算与基于计算机计算的一致性比较。
Intern Med J. 2016 May;46(5):583-9. doi: 10.1111/imj.13048.
5
A prospective survey of atrial fibrillation management in Iran: Baseline results of the Iranian Registry of Atrial Fibrillation (IRAF).伊朗心房颤动管理的前瞻性调查:伊朗心房颤动登记研究(IRAF)的基线结果。
Int J Clin Pract. 2021 Aug;75(8):e14313. doi: 10.1111/ijcp.14313. Epub 2021 May 13.
6
Do CHA2 DS2 VASc and HAS-BLED scores influence 'real-world' anticoagulation management in atrial fibrillation? 1556 patient registry from the reference cardiology centre.CHA2 DS2 VASc评分和HAS - BLED评分是否会影响心房颤动的“真实世界”抗凝管理?来自参考心脏病中心的1556例患者登记资料。
Pharmacoepidemiol Drug Saf. 2015 Dec;24(12):1297-303. doi: 10.1002/pds.3878. Epub 2015 Sep 30.
7
Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF).心房颤动抗凝治疗患者血栓栓塞和出血事件的风险因素:前瞻性、多中心观察性预防血栓栓塞事件-心房颤动欧洲登记研究(PREFER in AF)。
BMJ Open. 2019 Mar 30;9(3):e022478. doi: 10.1136/bmjopen-2018-022478.
8
Stroke Risk Status, Anticoagulation Treatment, and Quality-of-Life in Chinese Patients with Atrial Fibrillation: China Registry of Atrial Fibrillation (CRAF).中国心房颤动患者的卒中风险状况、抗凝治疗和生活质量:中国心房颤动注册研究(CRAF)。
Cardiovasc Ther. 2019 Mar 21;2019:7372129. doi: 10.1155/2019/7372129. eCollection 2019.
9
Real-World Clinical Characteristics and Treatment Patterns of Individuals Aged 80 and Older with Nonvalvular Atrial Fibrillation: Results from the ReAl-life Multicenter Survey Evaluating Stroke Study.80岁及以上非瓣膜性心房颤动患者的真实世界临床特征和治疗模式:评估卒中研究的真实生活多中心调查结果
J Am Geriatr Soc. 2017 Aug;65(8):1684-1690. doi: 10.1111/jgs.14855. Epub 2017 Apr 10.
10
The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2.心房颤动卒中预防的变化格局:GLORIA-AF 注册研究 2 期结果。
J Am Coll Cardiol. 2017 Feb 21;69(7):777-785. doi: 10.1016/j.jacc.2016.11.061.

引用本文的文献

1
Anticoagulation quality through time in therapeutic range in Sub-Saharan Africa: a systematic review and meta-analysis.撒哈拉以南非洲地区治疗范围内抗凝质量随时间变化的系统评价与荟萃分析。
Front Med (Lausanne). 2025 Mar 14;12:1517162. doi: 10.3389/fmed.2025.1517162. eCollection 2025.
2
The Atrial FibriLlatiOn Registry (FLOW-AF): Patient Characteristics, Treatment Patterns, and Outcomes in Egypt.心房颤动注册研究(FLOW-AF):埃及患者的特征、治疗模式及结局
Cardiol Ther. 2025 Jun;14(2):161-182. doi: 10.1007/s40119-025-00400-0. Epub 2025 Mar 21.
3
The Atrial Fibrillation Registry (The FLOW-AF Registry): Insights From the United Arab Emirates-Patient Characteristics, Treatment, and One-Year Outcomes.

本文引用的文献

1
Factors associated to adequate time in therapeutic range with oral vitamin K antagonists in Tunisia.突尼斯口服维生素K拮抗剂治疗范围内充足时间的相关因素。
Tunis Med. 2019 Jan;97(1):113-121.
2
Design and Rationale of the National Tunisian Registry of Atrial Fibrillation: Protocol for a Prospective, Multicenter Trial.突尼斯全国心房颤动登记处的设计与原理:一项前瞻性多中心试验方案
JMIR Res Protoc. 2018 Oct 15;7(10):e181. doi: 10.2196/resprot.8523.
3
Prevalence, clinical characteristics and outcomes of valvular atrial fibrillation in a cohort of African patients with acute heart failure: insights from the THESUS-HF registry.
心房颤动注册研究(FLOW-AF注册研究):来自阿拉伯联合酋长国的见解——患者特征、治疗及一年结局
J Cardiovasc Electrophysiol. 2025 Apr;36(4):813-823. doi: 10.1111/jce.16598. Epub 2025 Feb 10.
4
Comparison of anticoagulation control and outcomes between usual medical care and pharmacist-led anticoagulation service in ambulatory patients taking warfarin at tertiary hospital in Ethiopia: a quasi-experimental study.埃塞俄比亚一家三级医院中服用华法林的门诊患者接受常规医疗护理与药剂师主导的抗凝服务时抗凝控制及结局的比较:一项准实验研究。
J Pharm Health Care Sci. 2024 Jun 26;10(1):32. doi: 10.1186/s40780-024-00355-9.
5
The Atrial FibriLlatiOn (FLOW-AF) Registry in the Middle East and North Africa: Patient Characteristics, Treatment Patterns and Outcomes.中东和北非地区心房颤动(FLOW-AF)注册研究:患者特征、治疗模式及结局
Adv Ther. 2024 Jul;41(7):2868-2889. doi: 10.1007/s12325-024-02895-w. Epub 2024 May 27.
6
The Intersection of Atrial Fibrillation and Coronary Artery Disease in Middle Eastern Patients. Analysis from the Jordan Atrial Fibrillation Study.中东患者中心房颤动与冠状动脉疾病的交叉。来自约旦心房颤动研究的分析。
Glob Heart. 2024 Mar 12;19(1):29. doi: 10.5334/gh.1312. eCollection 2024.
7
Anticoagulation Management in Patients Receiving Warfarin at Private Cardiac Centers in Addis Ababa, Ethiopia.埃塞俄比亚亚的斯亚贝巴私立心脏中心接受华法林治疗患者的抗凝管理
J Blood Med. 2023 Feb 10;14:107-117. doi: 10.2147/JBM.S397189. eCollection 2023.
8
Anticoagulation control, outcomes, and associated factors in long-term-care patients receiving warfarin in Africa: a systematic review.非洲接受华法林治疗的长期护理患者的抗凝控制、结局及相关因素:一项系统评价
Thromb J. 2022 Oct 3;20(1):58. doi: 10.1186/s12959-022-00416-9.
9
One-Year Clinical Outcome in Middle Eastern Patients with Atrial Fibrillation: The Jordan Atrial Fibrillation (JoFib) Study.中东地区心房颤动患者的一年临床结局:约旦心房颤动(JoFib)研究
Int J Vasc Med. 2022 Apr 13;2022:4240999. doi: 10.1155/2022/4240999. eCollection 2022.
非洲急性心力衰竭患者队列中瓣膜性心房颤动的患病率、临床特征及结局:来自THESUS-HF注册研究的见解
Cardiovasc J Afr. 2018 May/Jun;29(3):139-145. doi: 10.5830/CVJA-2017-051.
4
Registries in Atrial Fibrillation: From Trials to Real-Life Clinical Practice.心房颤动登记研究:从试验到现实临床实践
Am J Med. 2017 Feb;130(2):135-145. doi: 10.1016/j.amjmed.2016.09.012. Epub 2016 Oct 13.
5
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.2016年欧洲心脏病学会(ESC)与欧洲心胸外科学会(EACTS)合作制定的心房颤动管理指南。
Eur Heart J. 2016 Oct 7;37(38):2893-2962. doi: 10.1093/eurheartj/ehw210. Epub 2016 Aug 27.
6
Atrial Fibrillation Management Strategies in Routine Clinical Practice: Insights from the International RealiseAF Survey.常规临床实践中的心房颤动管理策略:来自国际RealiseAF调查的见解
PLoS One. 2016 Jan 22;11(1):e0147536. doi: 10.1371/journal.pone.0147536. eCollection 2016.
7
Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF General Pilot Registry.欧洲心脏病学会指南指导下的抗栓治疗改善了高危房颤患者的预后:来自 EORP-AF 一般试点登记处的报告。
Europace. 2015 Dec;17(12):1777-86. doi: 10.1093/europace/euv269. Epub 2015 Aug 30.
8
Atrial fibrillation in Sub-Saharan Africa: epidemiology, unmet needs, and treatment options.撒哈拉以南非洲地区的心房颤动:流行病学、未满足的需求及治疗选择
Int J Gen Med. 2015 Jul 31;8:231-42. doi: 10.2147/IJGM.S84537. eCollection 2015.
9
Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry, Phase II.新发非瓣膜性心房颤动患者的抗血栓治疗模式:GLORIA-AF 登记研究,第二阶段。
Am J Med. 2015 Dec;128(12):1306-13.e1. doi: 10.1016/j.amjmed.2015.07.013. Epub 2015 Aug 1.
10
Active surveillance for rheumatic heart disease in endemic regions: a systematic review and meta-analysis of prevalence among children and adolescents.在风湿热流行地区进行风湿性心脏病的主动监测:儿童和青少年患病率的系统评价和荟萃分析。
Lancet Glob Health. 2014 Dec;2(12):e717-26. doi: 10.1016/S2214-109X(14)70310-9.